Management of Children with Juvenile Idiopathic Arthritis

详细信息    查看全文

• 作者：Vijay Viswanathan ; Kevin J. Murray
• 关键词：Juvenile idiopathic arthritis ; DMARDs ; Biologicals ; Uveitis
• 刊名：The Indian Journal of Pediatrics
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：83
• 期：1
• 页码：63-70
• 全文大小：260 KB
• 参考文献：1.Johnson K, Gardner-Medwin J. Childhood arthritis: classification and radiology. Clin Radiol. 2002;57:47–58.PubMed CrossRef
  2.McHugh K, Gupta R, Murray K. Imaging in juvenile chronic arthritis. Imaging. 1999;11:91–7.CrossRef
  3.Pedersen TK, Küseler A, Gelineck J, Herlin T. A prospective study of magnetic resonance and radiographic imaging in relation to symptoms and clinical findings of the temporomandibular joint in children with juvenile idiopathic arthritis. J Rheumatol. 2008;35:1668–75.PubMed
  4.Gylys-Morin VM. MR imaging of pediatric musculoskeletal inflammatory and infectious disorders. Magn Reson Imaging Clin N Am. 1998;6:537–59.PubMed
  5.Workie DW, Graham TB, Laor T, et al. Quantitative MR characterization of disease activity in the knee in children with juvenile idiopathic arthritis: a longitudinal pilot study. Pediatr Radiol. 2007;37:535–43.PubMed CrossRef
  6.Nistala K, Babar J, Johnson K, et al. Clinical assessment and core outcome variables are poor predictors of hip arthritis diagnosed by MRI in juvenile idiopathic arthritis. Rheumatology (Oxford). 2007;46:699–702.CrossRef
  7.Shanmugavel C, Sodhi KS, Sandhu MS, et al. Role of power Doppler sonography in evaluation of therapeutic response of the knee in juvenile rheumatoid arthritis. Rheumatol Int. 2008;28:573–8.PubMed CrossRef
  8.American College of Rheumatology, Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum. 2002;46:328–46.CrossRef
  9.Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63:465–82.CrossRef
  10.Brooks M. FDA approves tocilizumab for polyarticular JIA. Medscape Medical News. May 01, 2013.
  11.Giannini EH, Cassidy JT, Brewer EJ, Shaikov A, Maximov A, Kuzmina N. Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. Semin Arthritis Rheum. 1993;23:34–46.PubMed CrossRef
  12.Ruperto N, Murray KJ, Gerloni V, et al; Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral Mtx comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of Mtx. Arthritis Rheum. 2004;50:2191–201.
  13.Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral Mtx in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43:1849–57.PubMed CrossRef
  14.Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and the Cooperative Children’s Study Group. Engl J Med. 1992;326:1043–9.CrossRef
  15.Takken TJ, Van Der Net, Helders PJ. Methotrexate for treating juvenile idiopathic arthritis. Cochrane Database Syst Rev. 2001;4:CD003129.PubMed
  16.Ravelli A, Viola S, Migliavacca D, Ruperto N, Pistorio A, Martini A. The extended oligoarticular subtype is the best predictor of Mtx efficacy in juvenile idiopathic arthritis. J Pediatr. 1999;135:316–20.PubMed CrossRef
  17.Gottlieb BS, Keenan GF, Lu T, Ilowite NT. Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics. 1997;100:994–7.PubMed CrossRef
  18.Silverman E, Spiegel L, Hawkins D, et al. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2005;52:554–62.PubMed CrossRef
  19.Shi J, Kovacs SJ, Wang Y, Ludden TM, Bhargava VO. Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis. J Pharmacokinet Pharmacodyn. 2005;32:419–39.PubMed CrossRef
  20.Silverman E, Mouy R, Spiegel L, et al; Leflunomide in Juvenile Rheumatoid Arthritis (JRA) Investigator Group. Leflunomide or Mtx for juvenile rheumatoid arthritis. N Engl J Med. 2005;352:1655–66.
  21.Gao JS, Wu H, Tian J. Treatment of patients with juvenile rheumatoid arthritis with combination of leflunomide and Mtx. [Article in Chinese]. Zhonghua Er Ke Za Zhi. 2003;41:435–8.PubMed
  22.van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulphosalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum. 1998;41:808–16.PubMed CrossRef
  23.Burgos-Vargas R, Vázquez-Mellado J, Pacheco-Tena C, Hernández-Garduño A, Goycochea-Robles MV. A 26 week randomised double blind, placebo controlled exploratory study of Sulphosalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis. 2002;61:941–2.PubMed PubMedCentral CrossRef
  24.Hoza J, Kadlecová T, Nĕmcová D, Havelka S. Sulphasalazine and Delagil-a comparative study in patients with juvenile chronic arthritis. Acta Univ Carol Med (Praha). 1991;37:80–3.
  25.Cassidy JT, Petty RE, Laxer RM, Lindsley CB. Textbook of pediatric rheumatology. 5th ed. Canada: Elsevier Saunders; 2005.
  26.Brewer EJ, Giannini EH, Kuzmina N, Alekseev L. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial. N Engl J Med. 1986;314:1269–76.PubMed CrossRef
  27.Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P. Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2000;4:CD000959.PubMed
  28.Ruperto N, Ravelli A, Castell E, et al. Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol. 2006;24:599–605.PubMed
  29.Gerloni V, Cimaz R, Gattinara M, Arnoldi C, Pontikaki I, Fantini F. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology (Oxford). 2001;40:907–13.CrossRef
  30.Kvien TK, Hoyeraal HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol. 1986;13:118–23.PubMed
  31.Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68:635–41.PubMed CrossRef
  32.Hopkins SJ, Meager A. Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon. Clin Exp Immunol. 1988;73:88–92.PubMed PubMedCentral
  33.Grom AA, Murray KJ, Luyrink L, et al. Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy 3rd. Arthritis Rheum. 1996;39:1703–10.PubMed CrossRef
  34.Zhou H Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol. 2005;45:490–7.PubMed CrossRef
  35.Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2004;18:59–80.
  36.Nielsen S, Ruperto N, Gerloni V, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2008;26:688–92.PubMed
  37.Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342:763–9.PubMed CrossRef
  38.Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus Mtx for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096–106.PubMed CrossRef
  39.Lovell D, Ruperto N, Jung L, et al. Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis: 48-week results. Arthritis Rheum. 2006;54(Suppl):s303.
  
• 作者单位：Vijay Viswanathan (1) (2)
  Kevin J. Murray (3)
  
  1. Department of Pediatrics, Pediatric Rheumatology Clinic, Jupiter Hospital, Thane, Mumbai, India
  2. Department of Pediatrics, Pediatric Rheumatology Clinic, MGM New Bombay Hospital, Vashi, Mumbai, Maharashtra, 400703, India
  3. Department of Pediatrics, Pediatric Rheumatology Clinic, Princess Margaret Hospital for Children, Perth, Western Australia, Australia
  
• 刊物主题：Pediatrics; Gynecology;
• 出版者：Springer India
• ISSN：0973-7693

文摘

Juvenile idiopathic arthritis (JIA) comprises a group of heterogeneous disorders of chronic arthritis in childhood and remains the commonest pediatric rheumatic disease associated with significant long-term morbidity. Advances in understanding of the pathogenesis, better definition of disease control/remission measures, and the arrival of biological agents have improved the outcomes remarkably. Methotrexate (Mtx) remains the first-line disease modifying (DMARD) therapy for most children with JIA due to its proven efficacy and safety. Sulphosalazine (SSz) (especially for enthesitis) and leflunomide may also have a secondary role. Tumor necrosis factor inhibitors (TNF-I), alone or in combination with Mtx have shown tremendous benefit in children with polyarticular JIA, enthesitis related arthritis (ERA) and psoriatic arthritis. Tocilizumab appears very efficacious in systemic arthritis and abatacept and tocilizumab also appear to benefit polyarticular JIA; the role of rituximab remains unclear, though clearly beneficial in adult RA. TNF-I with Mtx is also effective in uveitis associated with JIA. Biologicals have demonstrated an impressive safety record in children with JIA, although close monitoring for rare but potentially dangerous adverse events, such as tuberculosis and other infections; paradoxical development of additional autoimmune diseases; and possibly an increased risk of cancers is warranted.